| Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment F Stanke-Labesque, E Gautier-Veyret, S Chhun, R Guilhaumou, ... Pharmacology & therapeutics 215, 107627, 2020 | 157 | 2020 |
| Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial … E Gautier-Veyret, X Fonrose, J Tonini, A Thiebaut-Bertrand, M Bartoli, ... Antimicrobial agents and chemotherapy 59 (4), 2305-2314, 2015 | 73 | 2015 |
| Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis E Gautier-Veyret, C Arnaud, M Bäck, JL Pépin, MH Petri, JP Baguet, ... European Respiratory Journal 42 (2), 404-413, 2013 | 66 | 2013 |
| A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug … T Willeman, JF Jourdil, E Gautier-Veyret, B Bonaz, F Stanke-Labesque Analytica chimica acta 1067, 63-70, 2019 | 64 | 2019 |
| Inflammation is a potential risk factor of voriconazole overdose in hematological patients E Gautier‐Veyret, A Truffot, S Bailly, X Fonrose, A Thiebaut‐Bertrand, ... Fundamental & clinical pharmacology 33 (2), 232-238, 2019 | 51 | 2019 |
| Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis F Stanke-Labesque, JL Pépin, E Gautier-Veyret, P Lévy, M Bäck Cardiovascular research 101 (2), 187-193, 2014 | 40 | 2014 |
| Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? JF Jourdil, D Lebert, E Gautier-Veyret, F Lemaitre, B Bonaz, G Picard, ... Analytical and bioanalytical chemistry 409, 1195-1205, 2017 | 37 | 2017 |
| Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015–2017) M Desnos-Ollivier, S Bretagne, A Boullié, C Gautier, F Dromer, ... Clinical Microbiology and Infection 25 (5), 634. e1-634. e4, 2019 | 35 | 2019 |
| Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates F Simon, E Gautier-Veyret, A Truffot, M Chenel, L Payen, ... Pharmaceutical Research 38, 415-428, 2021 | 32 | 2021 |
| Pharmacokinetic herb‐drug interaction between ginger and crizotinib B Revol, E Gautier‐Veyret, C Arrivé, N Fouilhé Sam‐Laï, A McLeer‐Florin, ... British Journal of Clinical Pharmacology 86 (9), 1892-1893, 2020 | 32 | 2020 |
| French Society of Pharmacology and Therapeutics Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug … F Stanke-Labesque, E Gautier-Veyret, S Chhun, R Guilhaumou Pharmacol. Ther 215 (107627), 10.1016, 2020 | 30 | 2020 |
| Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations E Gautier-Veyret, S Bailly, X Fonrose, J Tonini, S Chevalier, ... Pharmacogenomics 18 (12), 1119-1123, 2017 | 30 | 2017 |
| Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated E Gautier‐Veyret, A Thiebaut‐Bertrand, M Roustit, L Bolcato, J Depeisses, ... British journal of clinical pharmacology 87 (6), 2534-2541, 2021 | 26 | 2021 |
| Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography–tandem mass spectrometry JF Jourdil, B Némoz, E Gautier-Veyret, C Romero, F Stanke-Labesque Therapeutic Drug Monitoring 40 (4), 417-424, 2018 | 24 | 2018 |
| Combined impact of inflammation and pharmacogenomic variants on voriconazole trough concentrations: a meta-analysis of individual data L Bolcato, C Khouri, A Veringa, JWC Alffenaar, T Yamada, T Naito, ... Journal of Clinical Medicine 10 (10), 2089, 2021 | 22 | 2021 |
| Treatment by posaconazole tablets, compared to posaconazole suspension, does not reduce variability of posaconazole trough concentrations E Gautier-Veyret, L Bolcato, M Roustit, S Weiss, J Tonini, ... Antimicrobial Agents and Chemotherapy 63 (10), 10.1128/aac. 00484-19, 2019 | 20 | 2019 |
| Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome E Gautier-Veyret, M Bäck, C Arnaud, E Belaïdi, R Tamisier, P Lévy, ... Pharmacological Research 134, 311-319, 2018 | 20 | 2018 |
| Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits A Truffot, JF Jourdil, B Seitz-Polski, P Malvezzi, V Brglez, ... Clinical Biochemistry 87, 60-66, 2021 | 19 | 2021 |
| Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation E Bonneville, E Gautier‐Veyret, C Ihl, MN Hilleret, M Baudrant, X Fonrose, ... British Journal of Clinical Pharmacology 86 (9), 1888-1891, 2020 | 17 | 2020 |
| Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped. E Gautier-Veyret, X Fonrose, F Stanke-Labesque Clinical Pharmacology and Therapeutics 102 (2), 189-189, 2017 | 17 | 2017 |
